About
Jeff Stein, Ph.D., their President and Chief Executive Officer, was CEO of Trius Therapeutics, Inc., a publicly-traded pharmaceutical company, from its founding in 2007 until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. During his tenure, Trius developed the antibacterial drug tedizolid, which received marketing approval from the U.S. Food and Drug Administration in June 2014; tedizolid is now marketed under the name Sivextro. From 2005 to 2010, Dr. Stein was a venture partner at Sofinnova Ventures, a biotech venture capital fund. Prior to joining Sofinnova, Dr. Stein was co-founder and Chief Scientific Officer at Quorex Pharmaceuticals, Inc. from 1999 until its acquisition by Pfizer Pharmaceuticals, Inc. in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein currently serves on the Board of Directors of Great Lakes Pharmaceuticals, Inc., a private biopharmaceutical company, and Paratek Pharmaceuticals, a
Position in the VCSift Database
- • 51 investors hold the CEO & President role in VCSift. Jeffrey Stein is one of them.
- • 829 investors are based in San Diego, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- San Diego, US
Contact Information
Find more investors like Jeffrey
Search Investors